LSBio announces exclusive distribution agreements with select strategic partners

LifeSpan BioSciences, Inc. (LSBio), a leading provider of antibodies to researchers worldwide, today announced exclusive distribution agreements with select strategic partners making the full LSBio catalog of 75,000 antibodies, including 3,600 IHC-validated, IHC-plus™ antibodies, available around the globe. LSBio expects to improve international customer support by providing researchers worldwide with local access to the Company's vast catalog of high quality, well characterized and diverse reagents and antibodies.

“This agreement will also enable us to supply additional antibodies as LSBio continue the rapid expansion of their antibody portfolio.”

LSBio inked exclusive distribution partnerships with companies who have built solid reputations through significant experience in the biology space. Exclusive distribution relationships include:

• Asia Bioscience Co Ltd for Taiwan
• Biocom Biotech for South Africa
• Bio-Connect BV for The Netherlands, Belgium and Luxembourg
• Biozol Diagnostica Vertrieb GmbH for Germany
• CliniSciences s.a.s. for France
• Dong-in Biotech Co., Ltd for Republic of Korea
• IB Scientific for India
• LabForce AG for Switzerland
• Precision Technologies Pte Ltd for Singapore
• Sapphire Bioscience Pty. Ltd. for Australia and New Zealand
• Source Biosciences for the United Kingdom and Ireland

LSBio also sells their catalog of antibodies through the LSBio website and globally via non-exclusive distributors and the Antibodies-Online platform.

"Partnering with a leading-edge IHC-validated reagent antibodies supplier enables us to provide highly characterised, quality antibodies to our customers, which is critical to the growth of our products business," said Nick Ash, CEO at Source BioScience. "This agreement will also enable us to supply additional antibodies as LSBio continue the rapid expansion of their antibody portfolio."

"Our 15-year history in delivering IHC services and validating antibodies for use in IHC makes LSBio exceptionally qualified to meet the rising worldwide need for high-quality, IHC-validated antibodies," said LSBio CEO, Joe Brown, Ph.D. "By carefully selecting premier distributors who share that experience and understand the unique needs of the research community, we are able to provide one of the best customer support systems in the world for antibody reagents."

LSBio has grown its antibody business exponentially over the past three years, and researchers in more than 50 countries across Africa, Asia, Europe, North America, and South America now rely on LSBio for their antibodies.